2026 Final Agenda

Sponsored by: Structuring for Upside: Pairing Preferred Equity and Downstream Economics in Oncology Investing

Cancer Focus Fund pairs preferred equity with downstream milestone and royalty economics to de-risk investment while maximizing upside potential, backed by a unique investment partnership with MD Anderson Cancer Center.

Sponsored by: The Safety Layer for Outpatient CAR T and Bispecifics

No prophylaxis exists for CRS, so outpatient bispecifics and CAR T need continuous monitoring. FDA-cleared AION TempShield provides it, with 5,000+ high-risk patients monitored to date.

Sponsored by: First-in-Human Phase 1a Study Targeting Patients with Advanced Solid Tumors

CK1α is implicated in multiple oncogenic pathways and dysregulated across various solid tumors. PIN-5018, an oral CK1α-selective molecular glue degrader, demonstrates selective CK1α degradation and robust preclinical antitumor activity, and is currently in Phase 1a evaluation for safety, PK/PD, and preliminary efficacy.

Sponsored by: When RAS Inhibitors Hit Their Limits: Can a New Therapeutic Modality Change the Outcome? 

SiVEC has developed a programmable microbial technology to unlock new therapeutic strategies, deliberately tackling notoriously difficult RAS with an intracellular biologic engineered to exploit cancer's fundamental vulnerabilities and the signaling dependencies tumors must preserve.

Sponsored by: A Shifting Sea of Capital Access: Current Rising in Oncology

Oncology investment in 2026 has outpaced the previous four years. Continued pharma M&A activity and an active IPO market with sustained valuations gives exit potential for investors and LPs across biopharma. While we haven't seen the venture firm-level fundraising environment as robust as historically (at least on a total dollar basis), the investment landscape for biopharma does continue to be highly active—albeit, on a more concentrated basis. The confluence of these factors will continue to lead to strong teams and strong science being able to attract investors—though there will be a continued preference towards well-characterized biology and human data.

Sponsored by: Multi-Target T Cell Engagers for Solid Tumors

Deck Bio is developing multi-pMHC T cell engagers designed to broaden patient coverage and address tumor heterogeneity in solid tumors, led by preclinical program DBXO-1.

Sponsored by: Access as Oncology's Next Value Frontier

Breakthrough therapies create value only when they reach patients. This conversation explores how AI clears barriers between patients and therapy, and why access is becoming a strategic lever in oncology.

Sponsored by: Protecting the Asset: Keeping Patients in Trials

Up to 40% of enrolled oncology patients drop out before a trial completes, delaying readouts, burning runway, and eroding asset value. The causes are rarely clinical: they are financial, logistical, and emotional. We Are Here CEO Carolyn Treviño Jenkins, a cancer survivor and caregiver, shows how AI-matched support keeps patients enrolled.

Sponsored by: Beyond Trial Matching: Is AI Actually Accelerating Clinical Trials?

The clinical trials market is projected to grow ~6% annually, yet more trials don’t necessarily mean faster access for patients. This session explores how AI can accelerate the clinical trial journey end to end from trial planning and site selection through patient identification, enrollment, activation, and study completion. Moving beyond the narrow focus on patient-to-trial matching, an end-to-end approach that connects data, sponsors, sites, and patients with greater intelligence and transparency, holds the potential to create meaningful acceleration across the entire trial lifecycle.

Sponsored by: IP Findings That Change Valuation

What Oncology Companies Need to Know About Diligence, Clinical Trials, and Exclusivity

While IP issues don’t typically derail deals, they often reprice them. Learn how patent diligence, clinical trial disclosures, and global development strategies can affect exclusivity, valuation, financing, and IPO readiness.

Sponsored by: Scaling Radioligand Therapy Isotope Capacity

Gain insight to how well the medical isotopes and radiopharmceutical industry supply chain is positioned to support forecasted scale demands. Eden Radioisotopes is a new purpose built integrated reactor and processing facility specifically designed to make medical isotopes. Eden's production capacity for producing a variety of both diagnostic and radiotherapeutic medical isotopes will help assure a domestic supply to meet the forecasted growth needs of the future.